Effect of exendin-4 on lung function of diabetic patients: a preliminary report Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019
Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Pulmonary function of inhaled human insulin (Exubera®) in patients with type 1 diabetes: results from a 2-year study using standardized methodology Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006
Pulmonary function of inhaled human insulin (Exubera®) in patients with type 2 diabetes: results from a 2-year study using standardized methodology Source: Eur Respir J 2006; 28: Suppl. 50, 742s Year: 2006
A dual-acting muscarinic antagonist, ß2 -agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019
Association between antacid proton pump inhibitors and histamine 2 receptor antagonists) and incidence of lung cancer: a population-based cohort analysis Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Insulin therapy increases airway responsiveness in type 2 diabetes patients Source: Annual Congress 2008 - Cough and airway hyperresponsiveness Year: 2008
Does brain natriuretic peptide (BNP) at baseline influence the effects of nintedanib plus sildenafil in patients with IPF? Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019
Outcomes of a phase II study of ACT-293987, an oral IP receptor agonist, in pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab Source: Eur Respir J 2015; 46: 1740-1750 Year: 2015
Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001
Effect of inhaled human insulin (EXUBERA®; EXU) vs subcutaneous insulin (SC) on lung lining fluid constituents in adults with type 1 diabetes mellitus (T1DM) Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
Expression of glucocorticoid receptor beta (GCRβ) in asthmatic children and its correlation with clinical severity Source: Eur Respir J 2004; 24: Suppl. 48, 162s Year: 2004
Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 204s Year: 2005